These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12738671)

  • 1. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.
    Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; LeBlanc M; Gaynor ER; Rivkin SE; Fisher RI
    Blood; 2003 Sep; 102(5):1606-12. PubMed ID: 12738671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
    Press OW; Unger JM; Braziel RM; Maloney DG; Miller TP; Leblanc M; Fisher RI;
    J Clin Oncol; 2006 Sep; 24(25):4143-9. PubMed ID: 16896003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
    Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI
    J Clin Oncol; 2013 Jan; 31(3):314-20. PubMed ID: 23233710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
    Link BK; Martin P; Kaminski MS; Goldsmith SJ; Coleman M; Leonard JP
    J Clin Oncol; 2010 Jun; 28(18):3035-41. PubMed ID: 20458031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
    Jäeger G; Neumeister P; Brezinschek R; Höfler G; Quehenberger F; Linkesch W; Sill H
    Eur J Haematol; 2002 Jul; 69(1):21-6. PubMed ID: 12270058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus
    Shadman M; Li H; Rimsza L; Leonard JP; Kaminski MS; Braziel RM; Spier CM; Gopal AK; Maloney DG; Cheson BD; Dakhil S; LeBlanc M; Smith SM; Fisher RI; Friedberg JW; Press OW
    J Clin Oncol; 2018 Mar; 36(7):697-703. PubMed ID: 29356608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL.
    Fisher RI
    Clin Adv Hematol Oncol; 2005 Jul; 3(7):544-6. PubMed ID: 16167036
    [No Abstract]   [Full Text] [Related]  

  • 8. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
    Barr PM; Li H; Burack WR; LeBlanc M; Smith SM; Gopal AK; Floyd JD; Persky DO; Press OW; Fisher RI; Friedberg JW
    Lancet Haematol; 2018 Mar; 5(3):e102-e108. PubMed ID: 29396094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
    Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
    Smith MR; Li H; Gordon L; Gascoyne RD; Paietta E; Forero-Torres A; Kahl BS; Advani R; Hong F; Horning SJ
    J Clin Oncol; 2012 Sep; 30(25):3119-26. PubMed ID: 22851557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
    Hiddemann W; Kneba M; Dreyling M; Schmitz N; Lengfelder E; Schmits R; Reiser M; Metzner B; Harder H; Hegewisch-Becker S; Fischer T; Kropff M; Reis HE; Freund M; Wörmann B; Fuchs R; Planker M; Schimke J; Eimermacher H; Trümper L; Aldaoud A; Parwaresch R; Unterhalt M
    Blood; 2005 Dec; 106(12):3725-32. PubMed ID: 16123223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.
    Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Castellucci P; Marchi E; Farsad M; Fina M; Pellegrini C; Alinari L; Derenzini E; de Vivo A; Bacci F; Pileri S; Baccarani M
    Ann Oncol; 2008 Apr; 19(4):769-73. PubMed ID: 18303033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
    Domingo-Domènech E; González-Barca E; Estany C; Sureda A; Besalduch J; Fernández de Sevilla A
    Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
    Illidge TM; McKenzie HS; Mayes S; Bates A; Davies AJ; Pettengell R; Stanton L; Cozens K; Hampson G; Dive C; Zivanovic M; Tipping J; Gallop-Evans E; Radford JA; Johnson PW
    Br J Haematol; 2016 Apr; 173(2):274-82. PubMed ID: 26849853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
    Persky DO; Unger JM; Spier CM; Stea B; LeBlanc M; McCarty MJ; Rimsza LM; Fisher RI; Miller TP;
    J Clin Oncol; 2008 May; 26(14):2258-63. PubMed ID: 18413640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.
    Kelly JL; Salles G; Goldman B; Fisher RI; Brice P; Press O; Casasnovas O; Maloney DG; Soubeyran P; Rimsza L; Haioun C; Xerri L; LeBlanc M; Tilly H; Friedberg JW
    J Clin Oncol; 2015 May; 33(13):1482-90. PubMed ID: 25823738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment options have changed the survival of patients with follicular lymphoma.
    Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP
    J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
    Tomita N; Kodama F; Oshima R; Hashimoto C; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Sakai R; Fujita H; Fujisawa S; Kanamori H; Motomura S; Ishigatsubo Y
    Leuk Lymphoma; 2006 Jun; 47(6):1041-7. PubMed ID: 16840195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.